Diapositive 1

Gomez DR. et al. Lancet Oncol 2016

Median PFS time:

11.9 vs 3.9 months (p = 0.005)

Median time to new lesion:

11.9 vs 5.7 months (p = 0.049)



Local

consolidative therapy

with or without maintenance therapy for patients with

3 or fewer

metastases

from NSCLC

improved PFS

compared with maintenance therapy alone.



These findings suggest that

aggressive local therapy

should be

further explored in phase III

trials

as a standard treatment option in this scenario